MXCT
MaxCyte, Inc. Healthcare - Medical Devices Investor Relations →
MaxCyte, Inc. (MXCT) closed at $0.81 as of 2026-02-02, trading 79.5% below its 200-week moving average of $3.95. This places MXCT in the extreme value zone. The stock is currently moving closer to the line, down from -77.2% last week. With a 14-week RSI of 28, MXCT is in oversold territory.
Over the past 188 weeks of data, MXCT has crossed below its 200-week moving average 1 time. On average, these episodes lasted 188 weeks.
With a market cap of $86 million, MXCT is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -23.2%. The stock trades at 0.5x book value.
Share count has increased 4.5% over three years, indicating dilution.
Over the past 3.7 years, a hypothetical investment of $100 in MXCT would have grown to $15, compared to $176 for the S&P 500. MXCT has returned -40.6% annualized vs 16.7% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Growth of $100: MXCT vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After MXCT Crosses Below the Line?
Across 1 historical episodes, buying MXCT when it crossed below its 200-week moving average produced an average return of -21.0% after 12 months (median -21.0%), compared to +13.0% for the S&P 500 over the same periods. After 24 months, the average return was -20.0% vs +38.0% for the index.
Each line shows $100 invested at the moment MXCT crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
MXCT has crossed below its 200-week MA 1 time
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jul 2022 | Ongoing | 188+ | 79.5% | Ongoing | -83.5% |
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of Friday close, 2026-02-02